NCT02309450 - Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen | Biotech Hunter

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

August 31, 2016

Conditions

Hepatitis C Virus Genotype 4 Infection

Interventions

DRUG

.Asunaprevir, Daclatasvir and BMS - 791325

All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.

Trial Locations (1)

Unknown

France, All the Regions of the Country